About Us

BioTime is a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer (read more about BioTime).

Recently, BioTime announced the completion of its acquisition of Asterias Biotherapeutics, Inc., which added two cell therapy clinical stage programs to the Company’s pipeline.

BioTime common stock is traded on the NYSE American and TASE under the symbol BTX.

Connect with the company on  Twitter, LinkedIn, Facebook, and YouTube.